ArsenalBio Stock
ArsenalBio is a programmable cell therapy company.
Sign up today and learn more about ArsenalBio Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About ArsenalBio Stock
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. Founded in 2019, ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
Funding History
October 2019 | $85.0M |
---|
Management
Chief Technology Officer
Tarjei Mikkelsen
Chief Scientific Officer
Jane Grogan
CEO, President & Director
Ken Drazan
Press
news - Dec, 19 2022
Funding Falls For Startups Fighting Cancerendpts - Sep, 28 2022
ArsenalBio lands $70M cash deal with cancer giant Genentech to develop cell therapythepharmaletter - Sep, 28 2022
ArsenalBio bags $70 million upfront from Roche CAR-T dealnews - Sep, 9 2022
The Week’s 10 Biggest Funding Rounds: Mysten Labs’ $300M Round For Web3 Leads The Wayzpr - Sep, 9 2022
ArsenalBio Raises $220M As Cell Therapy’s Popularity Grows